Regenerative ophthalmology: Technologic and pharmacologic approaches to restoring sight via retinal prosthesis

R. Iezzi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Retinal prosthesis technology can restore rudimentary form vision in patients with retinitis pigmentosa (RP) who have lost all eyesight. This continually advancing field within regenerative ophthalmology represents the merger of micro-electromechanical systems technology with neurosensory retina. This man-machine interface is reliant upon the long-term health of a neurosensory retina undergoing progressive pathophysiologic changes. Pharmacologic approaches that address the pathophysiologic consequences of RP will likely play an important role for all regenerative treatment strategies.

Original languageEnglish (US)
Pages (from-to)33-35
Number of pages3
JournalClinical Pharmacology and Therapeutics
Volume99
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Visual Prosthesis
Retinitis Pigmentosa
Ophthalmology
Retina
Technology
Health
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Regenerative ophthalmology : Technologic and pharmacologic approaches to restoring sight via retinal prosthesis. / Iezzi, R.

In: Clinical Pharmacology and Therapeutics, Vol. 99, No. 1, 01.01.2016, p. 33-35.

Research output: Contribution to journalArticle

@article{e447bbb182844b0d844672bd6049022e,
title = "Regenerative ophthalmology: Technologic and pharmacologic approaches to restoring sight via retinal prosthesis",
abstract = "Retinal prosthesis technology can restore rudimentary form vision in patients with retinitis pigmentosa (RP) who have lost all eyesight. This continually advancing field within regenerative ophthalmology represents the merger of micro-electromechanical systems technology with neurosensory retina. This man-machine interface is reliant upon the long-term health of a neurosensory retina undergoing progressive pathophysiologic changes. Pharmacologic approaches that address the pathophysiologic consequences of RP will likely play an important role for all regenerative treatment strategies.",
author = "R. Iezzi",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/cpt.292",
language = "English (US)",
volume = "99",
pages = "33--35",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Regenerative ophthalmology

T2 - Technologic and pharmacologic approaches to restoring sight via retinal prosthesis

AU - Iezzi, R.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Retinal prosthesis technology can restore rudimentary form vision in patients with retinitis pigmentosa (RP) who have lost all eyesight. This continually advancing field within regenerative ophthalmology represents the merger of micro-electromechanical systems technology with neurosensory retina. This man-machine interface is reliant upon the long-term health of a neurosensory retina undergoing progressive pathophysiologic changes. Pharmacologic approaches that address the pathophysiologic consequences of RP will likely play an important role for all regenerative treatment strategies.

AB - Retinal prosthesis technology can restore rudimentary form vision in patients with retinitis pigmentosa (RP) who have lost all eyesight. This continually advancing field within regenerative ophthalmology represents the merger of micro-electromechanical systems technology with neurosensory retina. This man-machine interface is reliant upon the long-term health of a neurosensory retina undergoing progressive pathophysiologic changes. Pharmacologic approaches that address the pathophysiologic consequences of RP will likely play an important role for all regenerative treatment strategies.

UR - http://www.scopus.com/inward/record.url?scp=84955237091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955237091&partnerID=8YFLogxK

U2 - 10.1002/cpt.292

DO - 10.1002/cpt.292

M3 - Article

C2 - 26522735

AN - SCOPUS:84955237091

VL - 99

SP - 33

EP - 35

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -